VP1 372-380 (HLA-B*07:02)

VP1 372-380 (HLA-B*07:02)
€50.00 *

Prices plus VAT plus shipping costs

Delivery time 3 weeks
sterile and endotoxin free Delivery Format:
The product is supplied freeze dried as trifluoracetate salt

Amount in mg:

make your choice

  • EP11463_1
This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell... more
Product information "VP1 372-380 (HLA-B*07:02)"
This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assaysThis peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells. VPQYGYLTL is a linear peptidic epitope (epitope ID70458) studied as part of Capsid protein VP1 from Adeno-associated dependoparvovirus A. This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assays

 
Sequence:VPQYGYLTL
Gene:VP1
Delivery: 3 weeks
C-Terminus:OH
N-Terminus:H
Purity:95%
Amount:1 mg
Counter Ion:TFA
Protein:Major capsid protein VP1
Species:(HBoV1) (Human bocavirus type 1)
Allele:HLA-B*07:02
Application :T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response
Indication :Cancer;Gene therapy
Dokumente - Protokolle - Downloads more
Viewed